Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
- Biophytis launches OBA clinical development program for obesity treatment
- BIO101 shows promising preclinical results in addressing muscle loss due to obesity treatment
- GLP-1 receptor agonists play a significant role in weight loss but can lead to muscle loss
- Addressable market for obesity treatment expected to reach $100 billion by 2030
- BIO101's potential in treating obesity highlighted in Nature Biotechnology
- OBA Phase 2 clinical study to start in mid-2024 with results expected in 2025
- None.
Insights
The announcement by Biophytis SA regarding its preclinical results for BIO101 in obesity treatment presents a potential advancement in addressing muscle loss associated with obesity therapies. The combination of BIO101 with GLP-1 receptor agonists could represent a significant innovation, as current obesity treatments often lead to muscle mass reduction, which can undermine metabolic health and physical function.
Considering the projected market growth for anti-obesity medications, the successful development of BIO101 could position Biophytis to capture a substantial share of a market anticipated to expand dramatically by 2030. This could translate into a notable increase in the company's market valuation and investor interest. The focus on muscle preservation is a strategic differentiation, given the current gap in treatment options for obesity-related muscle wasting.
The obesity treatment market is rapidly expanding and Biophytis's approach to muscle preservation in this context could address a significant unmet medical need. The commercial potential for BIO101, should it receive regulatory approval, is underscored by the impressive market size and growth rate projections.
Investors should monitor the progress of the OBA Phase 2 clinical study closely, as positive outcomes could lead to increased partnership opportunities, potential licensing deals, or even buyout prospects from larger pharmaceutical companies seeking to expand their portfolios in the lucrative obesity treatment space.
Biophytis's strategic move to combine BIO101 with GLP-1 receptor agonists could tap into the existing market for GLP-1 RA drugs, which have already demonstrated efficacy in weight loss. The synergistic potential of this combination therapy could offer a competitive edge over existing treatments and align with the current industry trend towards personalized medicine.
From a market research perspective, the anticipation of regulatory approval and the expected start of the OBA Phase 2 clinical study in mid-2024 could influence investor sentiment and stock performance in the short term. Long-term implications hinge on the study's results and the subsequent steps towards commercialization.
Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (Nasdaq:BPTS)(Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces that it is launching a new clinical development program named OBA, with BIO101 (20-hydroxyecdysone) as a potential treatment for obesity in combination with GLP-1 receptor agonists.
Muscle loss due to obesity treatment: no therapy available today
Obesity treatment can lead to loss of muscle mass and function, notably as a consequence of dieting when combined with the recently introduced GLP-1 receptor agonists. Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs are very effective drugs that lead to significant weight loss. Up to
More than 15 million adults in the US will be treated with an anti-obesity medication by 2030, representing
Promising results already obtained in obesity
BIO101 (20-hydroxyecdysone) is the first oral daily MAS receptor activator and has demonstrated metabolic effects on muscle and fat tissues in preclinical studies in obesity. These benefical effects of BIO101 (20-hydroxyecdysone) may translate into improved mobility and muscle strength in obese sarcopenic patients, as suggested in the SARA-INT phase 2 study. Furthermore, the 20-hydroxyecdysone molecule was already tested in obese patients during hypocaloric dieting in the Quinolia study, showing promising effects on muscle strength and fat mass loss. BIO101's (20-hydroxyecdysone) potential in the treatment of obesity in combination with GLP-1RAs to counteract the undesirable effects on muscle wasting associated with drastic weight-loss was highlighted in Nature Biotechnology ("After obesity drugs' success, companies rush to preserve skeletal muscle") on March 05, 2024.
Stanislas Veillet, CEO of Biophytis, stated: "We believe BIO101 (20-hydroxyecdysone) has the potential to be the molecule of choice for preserving muscle function in patients suffering from obesity who are treated with GLP-1 RAs. Our drug candidate,subject to regulatory approvals, could contribute to meeting crucial medical challenges, while positioning Biophytis in a large market with incredibly high growth potential. We believe that our leadership in developing drugs for muscular diseases and promising results obtained in obesity will be a strong accelerator of the OBA clinical plan."
An accelerated clinical development with results expected in 2025
The OBA Phase 2 clinical study is expected to start mid 2024, upon regulatory approvals, with first patients expected to be treated in the second half of 2024. BIO101 (20-hydroxyecdysone) will be evaluated in obese patients treated with GLP-1 RAs, and following hypocaloric dieting. We expect the first results of the efficacy of our drug candidate to be available in 2025. Further information on the OBA program and the clinical study is expected to be provided through the coming weeks.
****
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular (sarcopenia, phase 3 ready and Duchenne muscular dystrophy), respiratory (Covid-19 phase 2-3 completed) and metabolic diseases (obesity, phase 2 to be started). The company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and the ADSs (American Depositary Shares) are listed on Nasdaq Capital Market (Ticker BPTS - ISIN: US09076G1040). For more information, visit www.biophytis.com
Disclaimer
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook,""believes,""expects,""potential,""continues,""may,""will,""should,""could,""seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of thesewords or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable.However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» section from the Company's 2023 FinancialReport available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information,future developments or otherwise, except as required by law.
Biophytis contacts
Investor relations
Nicolas Fellmann, CFO
Investors@biophytis.com
Media
Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50
SOURCE: Biophytis
View the original press release on accesswire.com
FAQ
What is the new clinical development program launched by Biophytis for obesity treatment?
What is the estimated addressable market size for obesity treatment by 2030?
What are the potential benefits of BIO101 in treating obesity?
When is the OBA Phase 2 clinical study expected to start?
What are the first results of BIO101's efficacy expected to be available?
